Small-molecule tyrosine kinase inhibitors (TKIs) suppress the growth of HER2+ breast cancer cells in vitro and tumor xenografts in vivo by inhibiting phosphorylation of ERBB receptor tyrosine kinases (RTKs) and thus preventing activation of downstream signaling mediators [7–9]. The gene discussed is ERBB2; the disease is breast carcinoma.